Cosciens Biopharma Inc (CSCIF)

[$avvyPenny$tockInvestor™]

KABOOOOMAGE FOR $AEZS is Imminent. $$$$$$$$$$$$$

Zoptarelin's Endpoints supporting approval
Just facts:
Endpoints supporting approval:
1. LIVE LONGER ---------------------------------------------------------Yes
2. BETTER QUALITY(see7)--------------------------------------------Yes
3. Improvement over available drugs--------------------------------Yes
4. Safer than alternatives------------------------------------------------Yes
5. Disease free survival EP2-------------------------------------------Yes
6. Stable disease was 44%, resulting in a Clinical Benefit Rate of 74%.
7. The overall survival after single agent zoptarelin doxorubicin is similar to that reported for modern triple combination chemotherapy, but was achieved with lower toxicity---------------------------------Yes

Aeterna Zentaris owns the worldwide rights except for China, Hong Kong and Macau, where rights have been out-licensed to Sinopharm

Zoptarelin doxorubicin is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Source AEZS - Google it

Please note that there are no SAFE drugs currently on the market.